CRYOFOCUS-B (06922) Sets 27 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express
03/17

Cryofocus Medtech (Shanghai) Co., Ltd. (CRYOFOCUS-B, 06922) has announced that its board of directors will convene on 27 March 2026. The agenda includes:

1. Reviewing and approving the Group’s audited financial results for the financial year ended 31 December 2025.

2. Deciding on the publication of the annual results announcement.

3. Considering a recommendation for the payment of a final dividend, if any.

The board currently comprises three executive directors—Mr. Li Kejian (Chairman), Mr. Zhu Jun and Mr. Liu Wei—two non-executive directors—Mr. Lv Shiwen and Mr. Zhao Chunsheng—and four independent non-executive directors—Dr. Gao Dayong, Mr. Liang Hsien Tse Joseph, Dr. Qin Zheng and Dr. Hu Henan.

The company released the notification in Hong Kong on 17 March 2026.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10